Preliminary Conference Programme

Wednesday 7 July 2021

10:00 - 11:00

Virtual exhibition & networking

11:00

Conference opening remarks

Dr Peter GREEN (Chairman, HEART UK)

 

Session 3: FH or not?

11:05 - 11:45

Introduction and Interactive cases linked to

Ms Kate HARALAMBOS (Cardiff, Wales, UK)


Polygenic hypercholesterolaemia: why do we want to know?
How knowing that a patient with clinical FH has a polygenic and not a monogenic cause for their phenotype is key in the clinician deciding on the appropriate patient care pathway

Prof Steve HUMPHRIES (London, UK)


VUS in FH

Dr Maggie WILLIAMS (Bristol, UK)

11:45 - 12:00

Break, virtual exhibition & networking

 

Session 2: Hyperlipidaemia educational updates

 

Co-chairs: Julian HalcoxHandrean Soran

12:00 - 12:20

Cardiac CT; the future of imaging

Why cardiac CT is useful for those with patients with raised cholesterol

Dr Derek CONNOLLY (Birmingham, UK)

12:20 - 12:40

Urine chemical medication analysis in the assessment of medication adherence

The presentation will cover the  how, the why and the when of using the test

Dr Pankaj GUPTA (Leicester, UK)

12:40 - 13:00

The impact of metabolic surgery on obesity related dyslipidaemia

Dr Safwaan ADAM (Manchester, UK)

13:00 - 13:40

Lunch, virtual exhibition & networking

 

Session 3: Lp(a)… what does it mean ?

 

Co-chairs: Jai Cegla + Dev Datta

13:40 - 14:00

Lp(a) measurement bias 

Over and underestimation of Lp(a) due to its different molecular weight isoforms has led to bias in many studies leading to underestimation of its strength as a cardiovascular risk factor

Dr Mike FRANCE (Manchester, UK)

14:00 - 14:20

How does Lp(a) fit with FH

Prof Paul DURRINGTON (Manchester, UK)

14:20 - 14:55

The role of Lp(a) and oxPLs in atherosclerosis

Current and future therapeutic agents and interventions targeting Lp(a) and oxPLs

Prof Sam TSIMIKAS (San Diego, USA)

14:55 - 15:15

Break, virtual exhibition & networking

 

Chair: Alan Rees

15:15 - 16:15

Session 4: Myant lecture:

Familial Hypercholesterolaemia: from Epidemiology to Genetics – a paradigm shift?

Clinical Certainties and Uncertainties: what remains unresolved?

Prof Andrew NEIL (Oxford, UK)

16:15

Day one close

Register here

Tuesday 13 July 2021

14:45 - 15:30

Virtual exhibition & networking

15:30 - 15:35

Welcome

15:35 - 16:25

Session 5: Oral abstract session

 

Medical & Scientific - Abstracts of free communications 

 

Co-chairs: Chris Byrne + Gordon Ferns

 

1

15:35 - 15:42                               

APOE gene testing in FH referrals – the story so far

Celia Duff-Farrier  (Bristol, UK)

 

15:42 - 15:45    Discussion                                           

 

2                                                   

15:45 - 15:52                               

Corneal confocal microscopy detects Small nerve fibre damage in patients with heterozygous familial hypercholesterolemia which ameliorated after treatment with PCSK9 inhibitor therapy

Maryam Ferdousi  (Manchester, UK)

 

15:52 - 15:55  Discussion                                                                                          

 

3                                                   

15:55 - 16:02                               

Frequency of Lipoprotein (a) Single Nucleotide Polymorphisms in patients undergoing Familial Hypercholesterolaemia genetic testing                                                      

Peter Carey  (Sunderland, UK)

 

16:02 - 16:05  Discussion                                                                                          

 

4

16:05 - 16:12                               

Genomic testing in patients with suspected Familial Chylomicronaemia Syndrome (FCS) and evaluation of the FCS clinical scoring tool                                                      

Julie Evans  (Bristol, UK)

 

16:12 - 16:15  Discussion                                                                                         

 

5                                                   

16:15 - 16:22                               

Small nerve fibre damage in patients with severe hypertriglyceridaemia

Alise Kalteniece  (Manchester, UK)

 

16:22 - 16:25  Discussion                                                                                          

 

16:25 - 17:15

Primary & Health Care - Abstracts of free communications

 

Co-chairs: Chris Allen + Nadeem Qureshi

 

6                                                                                

16:25 - 16:32                               

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis                                                      

Steve Humphries (London, UK)

 

16:32 - 16:35  Discussion                                        

 

7                                                                                

16:35 - 16:42                               

Does socioeconomic status have an effect on the treatment and outcomes of individuals with familial hypercholesterolaemia (FH)? : a cohort study of individuals with FH in UK primary care

Barbara Iyen (Nottingham, UK)

 

16:42 - 16:45   Discussion                                       

                                                      

8                                                                                

16:45 - 16:52                               

Identifying familial hypercholesterolemia (FH) in Hampshire general medical practices: a systematic approach – Interim Results               

Jayne Haigh (Hampshire, UK)

 

16:52 - 16:55  Discussion                                        

 

9

16:55 - 17:02                               

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records                                                      

Steve Humphries  (London, UK)

 

17:02 - 17:05  Discussion                                        

 

10                                                                              

17:05 - 17:12                               

The West Midland Familial Hypercholesterolaemia (FH) screening programme: Evaluating the utility of the 12 SNP polygenic risk score (PRS) across ethnic groupings                                                      

Maggie Williams  (Bristol, UK)

 

17:12 - 17:15   Discussion 

 

17:15 - 17:30

Break, virtual exhibition & networking

17:30 - 17:35

Presentation of certificates to oral abstract winners x 2

17:33 - 18:05

Sponsored symposium 1: 

 

Do we have the solutions to the gaps in our lipid treatment pathway?

Dr Derek CONNOLLY (Cardiologist, Birmingham, UK)

Dr Susan CONNOLLY (Cardiologist, Enniskillen, N Ireland)

 

Hosted by

18:05

Day two close

Register here

Thursday 15 July 2021

15:00 - 15:45

Virtual exhibition & networking

15:45 - 15:50

Welcome

15:50 - 16:20

Moderated poster session

 

Session moderators: Mike Khan + Alison Pottle

 

1

15:50 - 15:52                               

Absence of coronary artery calcium does not exclude coronary artery disease in FH patients

Alisha Israni (London, UK)

 

15:52 - 15:55  Q&A                                                                            

                                                      

2                                                                                                          

15:55 - 15:57                            

Lipoprotein (a) levels in monogenic versus polygenic hypercholesterolemia

Anjly Jain  (London, UK)

 

15:57 - 16:00  Q&A                                                                            

 

3                                                                                                          

16:00 - 16:02                              

Severe dyslipidaemia associated with dual heterozygosity for 2 genes causing hyperalpalipoproteinaemia

Eun Ji Kim  (London, UK)

 

16:02 - 16:05  Q&A                                                                            

 

4                                                                                                          

16:05 - 16:07                               

Prospective evaluation of the FAMCAT tool to identify Familial Hypercholesterolaemia (FH) in primary care

Arushan Kirubakaran  (London, UK)

 

16:07 - 16:10  Q&A

                                                                                                             

5                                                                                                          

16:10 - 16:12                              

The diagnostic yield for FH proband genetic testing is lower in postmenopausal women when fixed LDL-C decision thresholds are used                                                      

Ahai Luvai  (Newcastle, UK)

 

16:12 - 16:15  Q&A                     

                                                      

6                                                                                                          

16:15 - 16:17                              

Inpatient management of severe hypertriglyceridaemia at a tertiary centre

Wei Yang  (London, UK)

 

16:17 - 16:20  Q&A                                                                            

 

 

Session 6:  

 

Co-chairs: Alan FlanaganMike France

16:20 - 16:40

Considering CVD and the menopause

Ms Lynne INNES (Edinburgh, Scotland, UK)

16:40 - 17:00

Saturated fats and health

Prof Ian YOUNG (Belfast, N Ireland)

17:00 - 17:20

Speaker and presentation title tbc

17:20 - 17:35

Break, virtual exhibition & networking

17:35 - 17:40

Presentation of prizes to
- Rhianna Wingett award winner
- Poster abstract winners

17:40 - 18:10

Sponsored symposium 2

Hosted by

18:10

Day two close

Register here

Tuesday 20 July 2021 

15:00 - 15:45

Virtual exhibition & networking

 

Session 7: The Essential Cholesterol Programme for Primary Care + Allied Health Professionals

 

Co-chairs: Chris Allen + Michaela Nuttall

15:45 - 16:00

An introduction to the basics of cholesterol 

A cholesterol refresher with easy ways to remember what cholesterol is and why we need it.

Ms Michaela NUTTALL (Bromley, UK)

16:00 - 16:15

Understanding cholesterol results 

This presentation aims to outline how primary care should evaluate lipid results. 

The aim is not to know all the answers but not to miss any of the problems.

Dr Pete GREEN (Medway, UK)

 

Spotlight on diet and its impact on cholesterol

16:15 - 16:25

The impact of diet on cholesterol 
Mr Alan FLANAGAN (Surrey, UK)

16:25 - 16:35

Diet and cholesterol: from science to practice

Ms Lynne GARTON  (London, UK)

16:35 - 16:45

Joint discussion

16:45 - 17:00

Diabetes and cholesterol: exploring dietary factors

Ms Emma ELVIN (London, UK)

17:00 - 17:15

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects: The SAMSON Trial

60 patients with previous statin side effects were given alternating periods of statin, placebo and no treatment to determine what proportion of their side effects are due to the nocebo effect.

Dr James HOWARD (London, UK)

17:15 - 17:30

Break, virtual exhibition & networking

17:30 - 18:00

Sponsored symposium 3

Hosted by

18:00

Day three close

Register here

Thursday 22 July 2021

15:00 - 15:25

Virtual exhibition & networking

15:25 - 15:30

Introduction

15:30 - 16:30

Sponsored symposia 4
Part 1: Hosted by

 

Part 2:

Treating to target in Homozygous Familial Hypercholesterolaemia 
Improving outcomes and quality of life – a perspective through the eyes of a clinician and a patient 

 

Hosted by 

 

16:30 - 16:45

Break, virtual exhibition & networking

 

Session 8: Scientific session + hot topics

 

Co-chairs: Nigel Capps + Dermot Neely

16:45 - 16:50

Introduction 

16:50 - 17:10

Covid - it’s impact on healthcare

COVID and the response to COVID has had a wider health impact on the population and the legacy impact of care needs, than the virus itself.

This presentation aims to outline some of those impacts, particularly in relation to cardiovascular disease, and what's being done to address these issues. 

Dr Pete GREEN (Medway, UK)

17:10 - 17:30

NICE Guidelines and Technology Appraisals: How Does it Work?

Overview of the processes by which NICE devises guidelines, does drug technology and diagnostic assay appraisals.

Prof Tony WIERZBICKI (London, UK)

17:30 - 17:50

FH and the NHS LTP commitment 

The presentation will cover the ambition of the NHS Long Term Plan as it relates to familial hypercholesterolaemia and the progress made to date.

Prof Nick LINKER (London, UK)

17:50 - 18:00

Conference closing remarks

Dr Peter GREEN (Chairman, HEART UK)
Day four close

Final programme. The organisers reserve the right to change the programme at any time.

Register here